Research articles on GLP-1 medicines, peptides, nootropics, laboratory education, and grey-market quality are collected here in one current library. Browse by topic, read the latest publication cards, and expand the research context section when you want the evidence standards and editorial approach behind the summaries. Every article is educational research reference material—not medical advice, a treatment recommendation, or a substitute for a qualified clinician or the original study.
Latest research articles
-
GLP-1 Weight Regain After Stopping: What the New Pilot Trial Found
A small randomized trial from Tufts University and UT Southwestern tested whether digital wellness support or medically tailored meals could reduce early weight gain after GLP-1 therapy ended. Both approaches were associated with less modeled gain than usual care, but the study was exploratory, short, and too small to establish a maintenance standard.
-
Setmelanotide Hypothalamic Obesity Trial Correction: What Changed
A New England Journal of Medicine correction published October 14, 2026 changes how the TRANSCEND setmelanotide trial should be read. The correction aligns the published record with the FDA review of all 142 randomized participants, revises the placebo-adjusted BMI difference, and reports two deaths rather than one. The update does not erase the efficacy signal,…
-
Nisotirostide Obesity Trial: Can NPY2 Add More Weight Loss to GLP-1 Therapy?
A phase 1 study published October 3, 2026 provides the first detailed human evidence for nisotirostide, also known as LY3457263. The investigational NPY2 receptor agonist was tested alone and with dulaglutide, offering an early look at a non-incretin add-on strategy for GLP-1 obesity research.
-
Semaglutide Alzheimer’s Trial Results: What EVOKE Found
The largest clinical test of a GLP-1 drug in Alzheimer’s disease has now answered an important question. In the EVOKE and EVOKE+ phase 3 trials, oral semaglutide did not significantly slow cognitive or functional decline in 3,808 adults with early, amyloid-confirmed Alzheimer’s disease. The findings separate promising metabolic and laboratory signals from proven clinical benefit…
-
HD1916 Semaglutide Trial: What Phase 3 Results Mean
A randomized phase 3 trial published October 7, 2026 found that chemically synthesized semaglutide HD1916 produced weight loss within its therapeutic-equivalence margin compared with reference semaglutide. The 462-person Chinese trial is important for follow-on GLP-1 development, but it does not establish FDA approval, interchangeability, long-term safety, or suitability of unapproved products.
-
Survodutide Type 2 Diabetes Trial: What SYNCHRONIZE-2 Found
The October 1, 2026 publication of SYNCHRONIZE-2 provides the first detailed phase 3 results for survodutide in adults with both type 2 diabetes and overweight or obesity. In 752 participants treated for 76 weeks, the investigational glucagon/GLP-1 dual agonist produced greater weight loss and HbA1c reductions than placebo. The results add late-stage evidence while showing…
-
Pep19 Obesity Trial: Fat Distribution Improved Without Weight Loss
A new randomized clinical trial has given Pep19 its most important human test yet. In adults with obesity, the oral peptide changed abdominal fat distribution and improved insulin-related markers without producing significant weight loss. The result points to a different metabolic strategy, but the study was small, short, and not enough to establish clinical effectiveness…
-
FDA GLP-1 Green List: What Changed in the October 2026 Import Alert
The FDA revised Import Alert 66-80 on October 9, 2026, adding orforglipron entries, expanding product codes, and detailing records manufacturers may need to show CGMP compliance. The update concerns imported GLP-1 active pharmaceutical ingredients and detention without physical examination; it does not approve unapproved GLP-1 products or create a consumer purchasing pathway.
-
Vitamin B1 Deficiency and Vision Loss in GLP-1 Users: What the New Evidence Shows
The phrase “GLP-1s cause blindness” combines two different safety questions. New 2026 evidence describes a rare but serious vitamin B1 deficiency pathway involving prolonged vomiting, inadequate food intake, rapid weight loss, and Wernicke encephalopathy. Separate studies and regulator warnings address NAION, a rare optic-nerve disorder associated most consistently with semaglutide. This evidence review explains what…
-
Trenbolone Dermal Exposure: What New Doping Tests Show
A new Journal of Analytical Toxicology study shows that even trace dermal exposure to trenbolone and metenolone can produce detectable urinary metabolites. The findings do not establish how common accidental transfer is, but they give anti-doping laboratories better evidence for interpreting positive tests and evaluating contamination claims.
Research context, evidence standards, and editorial approach
How to Use These Research Articles
Start with the topic links above to narrow the library, then open an article that matches your question. Compound profiles provide a quick orientation to names, mechanisms, research status, and linked literature, while full research articles explain study design, reported outcomes, and important limitations in more detail. Use publication dates and categories to understand context, and follow source links when you need to check the underlying paper, regulatory notice, or public record.
How We Read the Evidence
A finding in a randomized human trial does not carry the same weight as an observational association, an animal experiment, or an in-vitro result. When reading research articles, check the population, comparison group, sample size, follow-up period, measured endpoint, and whether the result was a primary or exploratory analysis. A plausible mechanism can explain why a compound is being studied, but it cannot establish human safety or efficacy by itself. We also separate approved medicines from investigational compounds and research-use-only materials so readers do not confuse biological interest with regulatory status.
Questions to Ask Before Drawing a Conclusion
- Was the study conducted in humans, animals, cells, or a laboratory model?
- Was there a control or comparison group, and was the study large enough to support the claim?
- Does the reported endpoint measure a meaningful outcome or only a short-term marker?
- Are the results peer reviewed, publicly registered, and reproducible?
- Does the article link to the primary source so the methods and limitations can be checked?
- What remains unknown, especially about long-term safety, product quality, or generalizability?
Editorial Approach and Primary Sources
GLP1Place aims to make technical research easier to follow without turning uncertain findings into promises. Articles identify whether evidence is clinical, observational, preclinical, mechanistic, or regulatory, and they use cautious language when a study cannot establish cause and effect. For primary literature, compare the article summary with PubMed research results and the original publication whenever a claim matters. Sources may change over time, so readers should verify current notices and consult qualified professionals for personal medical decisions.
Keeping Research Current
Research moves quickly, especially in obesity medicine, peptide science, cognitive research, and product-quality oversight. A newer paper may add context without overturning every earlier finding, while an agency alert or later correction can change how a claim should be understood. For that reason, this Blog page is organized as a living research library rather than a static list of conclusions. Check publication dates, read the most recent update when available, and treat headlines as a guide to the evidence—not as proof that a compound works, is safe, or is appropriate for a particular person. This page also connects related topics so readers can compare clinical research with preclinical studies and regulatory reporting in the same subject area.
Educational and research reference only: the information on GLP1Place is not medical advice, a diagnosis, or a treatment recommendation.
Use category archives to compare related reports and compound profiles; the date, category, and source context help explain how each item fits the broader research record. When a claim matters, start with the linked primary source and the relevant regulatory notice.